Previous 10 | Next 10 |
GSK receives exclusive global license option for XMT-2056 Mersana to receive $100 million upfront option purchase fee If GSK exercises its option, Mersana to receive exercise payment; potential for additional development, regulatory and commercial milestone payments, plu...
Major earnings expected after the bell on Monday include: 3D Systems ( DDD ) Lemonade ( LMND ) Novavax ( NVAX ) Take-Two Interactive Software ( TTWO ) Upstart Holdings ( UPST ) For further details see: Notable earnings after Monday's close...
CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
CAMBRIDGE, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
Gainers: Super Micro Computer ( SMCI ) +16% . Tabula Rasa HealthCare. ( TRHC ) +10% . Martin Midstream Partners ( MMLP ) +7% . Seres Therapeutics ( MCRB ) +5% . Mersana Therapeutics ( MRSN ) +4% . Losers: OneSmart Interna...
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with this event. For further details see: Mersana Therapeutics (MRSN) Investor Presentation - Slideshow
Mersana Therapeutics (NASDAQ:MRSN) said Bain Capital Life Sciences managing director Andrew Hack this week bought 350K shares of the company at $2.91-$3.41, worth ~$1.1M. The clinical stage biotech disclosed the share purchases in a form 4 SEC filing from Wednesday. Bain Capital Life Sciences...
The shares of Mersana Therapeutics (NASDAQ:MRSN) surged in the pre-market Thursday after the clinical-stage biotech announced that the U.S. Food and Drug Administration (FDA) awarded it the orphan drug designation to XMT-2056 as a treatment for gastric cancer. Gastric cancer makes up nearly 1...
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced...
Mersana Therapeutics, Inc. (MRSN) Q1 2022 Earnings Conference Call May 09, 2022 08:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations and Corporate Communications Anna Protopapas - President, CEO & Director Arvin Yang - Senior VP & Chief Medical O...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...